These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 23828131

  • 1. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A.
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [Abstract] [Full Text] [Related]

  • 2. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A, Gumruk F, Gurgey A.
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A, de Bisotti R, Sumoza D, Fairbanks V.
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 9. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A, Rigano P, Troia A, Calzolari R, Scazzone C, Maggio A, Steinberg MH, Di Marzo R.
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [Abstract] [Full Text] [Related]

  • 10. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Jan; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 11. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM.
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
    Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH.
    Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
    [Abstract] [Full Text] [Related]

  • 14. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Apr 02; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 17. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.
    Am J Hematol; 2003 Feb 02; 72(2):121-6. PubMed ID: 12555216
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F, Bejaoui M.
    Arch Pediatr; 2008 Jan 02; 15(1):24-8. PubMed ID: 18164913
    [Abstract] [Full Text] [Related]

  • 20. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul 02; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.